Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease.

abstract：:Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wang D,Liu T,Shi S,Li R,Shan Y,Huang Y,Hu D,Huang C

更新日期：2016-11-01 00:00:00

abstract：:BACKGROUND: The effectiveness of antisense oligodeoxynucleotides for in vitro and in vivo studies is limited by a low efficiency of cellular uptake and instability due to degradation by nucleases. To overcome some of these problems, we recently developed a transfer method that utilizes inactivated Sendai virus (hemagg...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Morishita R,Gibbons GH,Horiuchi M,Nakajima M,Ellison KE,Lee W,Kaneda Y,Ogihara T,Dzau VJ

更新日期：1997-07-01 00:00:00

abstract：INTRODUCTION:Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased s...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hanson SFL,Terry MH,Moretta DT,Power GG,Wilson SM,Alam F,Ahsan F,Blood AB,Giri PC

更新日期：2018-09-01 00:00:00

abstract：:Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of car...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Salinas G,Rangasetty UC,Uretsky BF,Birnbaum Y

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:The well-described morning peak in the onset of acute coronary syndromes has been partly attributed to increased platelet activity upon arising. It has been suggested that stent thrombosis (ST) exhibits a similar pattern. We assessed whether a diurnal variation in ST occurs, and whether more robust antiplate...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Mogabgab O,Wiviott SD,Cannon CP,Sloan S,Sabatine MS,Antman EM,Braunwald E,Giugliano RP

更新日期：2013-11-01 00:00:00

abstract：:The National Heart, Lung, and Blood Institute convened a Workshop on September 20-21, 2010, "New Horizons in Cardioprotection," to identify future research directions for cardioprotection against ischemia and reperfusion injury. Since the early 1970s, there has been evidence that the size of a myocardial infarction co...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kloner RA,Schwartz Longacre L

更新日期：2011-09-01 00:00:00

abstract：:Approximately 40% of heart attack survivors remain at increased risk of recurrent cardiovascular events, despite the current treatment options showing that atherothrombosis is not exclusively a disorder of lipoprotein aggregation in the arterial wall. Clinical and experimental data suggest that inflammation plays an i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kottoor SJ,Arora RR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Varagic J,Susic D,Slama M,Frohlich ED

更新日期：2003-06-01 00:00:00

abstract：:We investigated the effect of erythropoietin (EPO) posttreatment on survival time and vascular functions in a mouse model of sepsis. Sepsis was induced by cecal ligation and puncture. After 20 ± 2 hours of sepsis, thoracic aorta was isolated for assessing its reactivity to norepinephrine (NE) and acetylcholine (ACh). ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kandasamy K,Choudhury S,Singh V,Addison MP,Darzi SA,Kasa JK,Thangamalai R,Dash JR,Kumar T,Sultan F,Singh TU,Parida S,Mishra SK

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Intimal hyperplasia following percutaneous interventional vascular procedures is a major cause of restenosis. Although heparin inhibits intimal hyperplasia, it has not proven clinically useful in part due to an inadequate duration of intramural drug residence. This study was designed to evaluate the efficacy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sasseen BM,Gray BD,Gal D,Lorinc R,Carpenter DC,Klugherz BD,Wilensky RL

更新日期：2001-10-01 00:00:00

abstract：:Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of beta 1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chron...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Vittorio TJ,Zolty R,Kasper ME,Khandwalla RM,Hirsh DS,Tseng CH,Jorde UP,Ahuja K

更新日期：2008-03-01 00:00:00

abstract：BACKGROUND:Insulin resistance (IR) is a well-known risk factor for cardiovascular complications. This study aimed to investigate the effect of a dietary model of IR in mice on cardiac remodeling, cardiac β-arrestin2 signaling, and the protective effects of carvedilol as a β-arrestin-biased agonist. METHODS AND RESULTS...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ibrahim WS,Ibrahim IAAE,Mahmoud MF,Mahmoud AAA

更新日期：2020-07-01 00:00:00

abstract：:We evaluated whether carotenoid astaxanthin (ASX) could prevent oxidative and atherosclerotic damage in rabbits. Rabbits received regular chow (control) or an atherogenic diet (1% cholesterol) alone or supplemented with 50, 100, and 500 mg% ASX for 60 days (n = 5-9 per group). The atherogenic diet increased the serum ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Augusti PR,Conterato GM,Somacal S,Sobieski R,Quatrin A,Maurer L,Rocha MP,Denardin IT,Emanuelli T

更新日期：2009-12-01 00:00:00

abstract：:BACKGROUND: Digoxin improves baroreflex function and reduces neurohumoral activation in severe heart failure, but it is uncertain how digoxin affects ventricular remodeling and progression to left ventricular dysfunction. In addition, the effect of digoxin in in vitro beta-adrenoceptor density and function, and contra...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sullebarger JT,D'Ambra PM,Clark LC,Thanikarry L,Fontanet HL

更新日期：1998-10-01 00:00:00

abstract：:Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomit...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ilebekk A,Eriksen M,Sevre K,Aspelin T,Björkman JA,Lyberg T,Nordlander M

更新日期：2006-09-01 00:00:00

abstract：:Homing of cardiac myosin-specific CD4-positive T cells into the myocardium is the initial pathologic event of experimental autoimmune myocarditis (EAM). Subsequently, various bystander inflammatory cells are recruited into the myocardium crossing vascular endothelial cell walls. Sulfated polysaccharide fucoidan binds ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tanaka K,Ito M,Kodama M,Tomita M,Kimura S,Hoyano M,Mitsuma W,Hirono S,Hanawa H,Aizawa Y

更新日期：2011-03-01 00:00:00

abstract：OBJECTIVE:Acute lung injury is a common complication after cardiopulmonary bypass (CPB). Oxidative damage greatly impacts CPB-induced lung ischemic pathogenesis and may represent a target for treatment. We aimed to investigate whether curcumin upregulates heme oxygenase 1 (HO-1) expression and ameliorates lung injury i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Liu K,Chen HL,Huang H,Jing H,Dong GH,Wu HW,You QS

更新日期：2012-12-01 00:00:00

abstract：:BACKGROUND: Circulating cells influence myocardial function during ischemia and reperfusion, (eg, neutrophils exacerbate, and platelets protect the myocardium from deterioration). This study was designed to determine the role of red blood cells on myocardial function following ischemia and reperfusion in isolated rat ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Yang BC,Nichols WW,Mehta JL

更新日期：1996-10-01 00:00:00

abstract：BACKGROUND:We hypothesized that the cardioprotective effect of angiotensin II (AngII) type 1 receptor (AT(1)R) blockade during in vivo ischemia-reperfusion (IR) might be associated with an increase in AngII type 2 receptor (AT(2)R) protein, as well as 1,4,5-inositol trisphosphate type 2 receptor (IP(3)R) and protein ki...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Jugdutt BI,Xu Y,Balghith M,Moudgil R,Menon V

更新日期：2000-10-01 00:00:00

abstract：:The antiarrhythmic potential of postconditioning in in vivo models remains poorly defined. We compared the effects of pre- and postconditioning on ventricular arrhythmogenesis against controls with and without reperfusion. Wistar rats (n = 40, 269 ± 3 g) subjected to ischemia (30 minutes)--reperfusion (24 hours) were ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kolettis TM,Vilaeti AD,Tsalikakis DG,Zoga A,Valenti M,Tzallas AT,Papalois A,Iliodromitis EK

更新日期：2013-07-01 00:00:00

abstract：INTRODUCTION:Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF). Our purpose was to evaluate the comparative effect on urine output (UO) and renal function between these regimens. METHODS:A retrospective study of hospitali...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ng TM,Konopka E,Hyderi AF,Hshieh S,Tsuji Y,Kim BJ,Han SY,Phan DH,Jeng AI,Lou M,Elkayam U

更新日期：2013-07-01 00:00:00

abstract：BACKGROUND:The oral vasopressin-2 receptor antagonist, tolvaptan, causes aquaresis and improves symptoms in patients with congestive heart failure. However, few studies have explored the effect of tolvaptan in acute heart failure (AHF) patients ≥90 years old. METHODS:This study enrolled 106 AHF patients treated with t...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sato Y,Uzui H,Mukai M,Shiomi Y,Hasegawa K,Ikeda H,Tama N,Fukuoka Y,Morishita T,Ishida K,Kaseno K,Miyazaki S,Nakano A,Tada H

更新日期：2020-01-01 00:00:00

abstract：:The effects of nitric oxide (NO) and noradrenergic activation in the posterior hypothalamus on arterial pressure tolerance induced by subcutaneous injection of nitroglycerin (NTG) was investigated in anesthetized Sprague-Dawley rats. Intravenous injections of NTG (3, 10, and 30 microg/kg) and sodium nitroprusside (1, ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Guettler DL,Ma SX

更新日期：2008-06-01 00:00:00

abstract：:Prior studies have suggested that intravenous diltiazem reduces the probability of spontaneous conversion of atrial fibrillation (AF) to sinus rhythm in the electrophysiology laboratory and in patients with postoperative AF. Whether diltiazem exerts the same effect in patients presenting to the emergency department (E...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hassan S,Slim AM,Kamalakannan D,Khoury R,Kakish E,Maria V,Ahmed S,Pires LA,Kronick SL,Oral H,Morady F

更新日期：2007-09-01 00:00:00

abstract：:A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh N

更新日期：2002-04-01 00:00:00

abstract：:BACKGROUND: Micropuncture studies were performed to determine the intrarenal hemodynamic effects of two conventional antihypertensive agents, hydrochlorothiazide (HCTZ) and hydralazine (HYDR) alone and in combination. METHODS AND RESULTS: Male spontaneously hypertensive and normotensive Wistar Kyoto rats (19 weeks old...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Komatsu K,Numabe A,Ono Y,Frohlich ED

更新日期：1996-01-01 00:00:00

abstract：BACKGROUND:Mortality after acute myocardial ischemia has been reduced by aspirin (ASA) but mechanisms other than the antiplatelet effect have not been established. This article evaluates an antiarrhythmic action during sympathetic stimulation in the intact anesthetized dog with and without ischemia. METHODS AND RESULT...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Shehadeh AA,Arena J,Moschos CB,Regan TJ

更新日期：2000-04-01 00:00:00

abstract：:BACKGROUND: The electrophysiologic mechanisms of the persistence of atrial fibrillation (AF) after its initiation are not well understood. Therefore, the electrophysiologic characteristics of the right atrium were evaluated in an acute, pacing-induced model of AF in the pig in order to identify parameters associated w...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Rahme MM,Cotter B,Leistad E,Subudhayangkul S,Wadhwa M,Ungab G,Feld GK

更新日期：1999-04-01 00:00:00

abstract：:BACKGROUND: The tendency for the electrophysiologic effect of class III antiarrhythmic agents (action potential prolongation) to be diminished at faster heart rates represents a major drawback of this class of drug and is usually referred to as "reverse use dependence." A novel class III agent, MS-551, has recently be...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Nakaya Y,Martin DK,Campbell TJ

更新日期：1997-01-01 00:00:00

abstract：:BACKGROUND: Clinical trials have shown that the use of lipid-lowering agents in postmyocardial infarction (MI) patients reduces rates of subsequent coronary events, reduces coronary artery bypass surgery rates, and improves survival. Physician decisions to prescribe lipid-lowering drugs is influenced by a number of pa...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Khan M,Mukkamala A,Taylor DK,Espinosa A,Duff J

更新日期：1998-07-01 00:00:00